Yahoo
OTC Markets OTCPK - Delayed Quote USD

Acura Pharmaceuticals, Inc. (ACUR)

0.0003 0.0000 (0.00%)
At close: November 6 at 4:00:00 PM EST
Chart Range Bar
Loading chart for ACUR
  • Previous Close 0.0003
  • Open 0.0004
  • Bid --
  • Ask --
  • Day's Range 0.0004 - 0.0004
  • 52 Week Range 0.0001 - 0.0100
  • Volume 400
  • Avg. Volume 1,524
  • Market Cap (intraday) 19,800
  • Beta (5Y Monthly) 55.06
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

www.acurapharm.com

9

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ACUR
40.00%
S&P 500 (^GSPC)
7.76%

1-Year Return

ACUR
40.00%
S&P 500 (^GSPC)
9.77%

3-Year Return

ACUR
0.00%
S&P 500 (^GSPC)
68.96%

5-Year Return

ACUR
99.95%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY17
Revenue 2.72M
Earnings 405k
Profit Margin 14.91%

Q2

FY16

Q3

FY16

Q4

FY16

Q1

FY17

-2M
0
2M
-1000.0%
-500.0%
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -56.24%

  • Return on Assets (ttm)

    -58.46%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.56M

  • Net Income Avi to Common (ttm)

    -879k

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    84.27%

  • Levered Free Cash Flow (ttm)

    -1.1M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: